Mark Garner received his PhD in biochemistry from Michigan State University. As part of his graduate work, Mark invented the now universally used gel-shift or “EMSA” assay for the study of protein–DNA interactions. Mark was then successively an American Cancer Society postdoctoral fellow and National Research Service Awardee at the NIH, and also completed a second postdoc at the University of Wisconsin-Madison. During this time, Mark also developed a long-term relationship with the Max Planck Institut für Biophysikalische Chemie in Göttingen. Mark returned to the NIH where he carried out fundamental research on capillary electrophoresis of nucleic acids and the molecular biophysics of macromolecular crowding and its effects on cellular processes. Since entering the private sector, Mark has worked with several cutting-edge companies and is currently global cancer segment manager with Agilent Technologies. Mark is based in Toronto, Canada.
Articles by Mark M. Garner, PhD
